Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Current Deferred Revenue (2016 - 2018)

Historic Current Deferred Revenue for Immucell (ICCC) over the last 8 years, with Q3 2018 value amounting to $24100.0.

  • Immucell's Current Deferred Revenue changed N/A to $24100.0 in Q3 2018 from the same period last year, while for Sep 2018 it was $24100.0, marking a year-over-year change of. This contributed to the annual value of $24100.0 for FY2017, which is 2881.62% down from last year.
  • Immucell's Current Deferred Revenue amounted to $24100.0 in Q3 2018.
  • Over the past 5 years, Immucell's Current Deferred Revenue peaked at $33856.0 during Q3 2016, and registered a low of $6690.0 during Q3 2014.
  • Over the past 5 years, Immucell's median Current Deferred Revenue value was $24100.0 (recorded in 2017), while the average stood at $20464.7.
  • Within the past 5 years, the most significant YoY rise in Immucell's Current Deferred Revenue was 2881.62% (2017), while the steepest drop was 2881.62% (2017).
  • Quarter analysis of 5 years shows Immucell's Current Deferred Revenue stood at $6690.0 in 2014, then changed by 0.0% to $6690.0 in 2015, then surged by 406.07% to $33856.0 in 2016, then decreased by 28.82% to $24100.0 in 2017, then changed by 0.0% to $24100.0 in 2018.
  • Its Current Deferred Revenue was $24100.0 in Q3 2018, compared to $24100.0 in Q2 2018 and $24100.0 in Q1 2018.